BioAtla Inc (NAS:BCAB)

Q2 2025 Bioatla Inc Earnings Call Transcript

Aug 7, 2025 / 08:30 PM GMT

Release Date Price: $19 (+1.41%)

Transcript 10-Q8-K

Key Points

Positve

BioAtla Inc (BCAB) reported progress in their phase one dose escalation study for BA 3,182, showing objective tumor reductions in heavily pre-treated adenocarcinoma patients.
The company has demonstrated a compelling overall response rate (ORR) of 45% in metastatic HPV positive head and neck cancer, significantly higher than the standard of care.
BioAtla Inc (BCAB) is on track for a phase one data readout for BA 3,182 in the second half of the year, with further dose expansion data expected in the first half of 2026.
The company has reduced its research and development expenses by $2.5 million compared to the previous year, reflecting effective cost management.
BioAtla Inc (BCAB) is in advanced stages of partnership discussions, with diligence completed for one asset and a term sheet stage reached, indicating potential non-dilutive funding opportunities.

Negative

BioAtla Inc (BCAB) reported a net loss of $18.7 million for the quarter, although this is an improvement from the previous year.
Cash and cash equivalents have decreased significantly to $18.2 million as of June 30, 2025, from $49 million at the end of 2024.
The company is primarily relying on non-dilutive funding through partnerships, which may pose a risk if such partnerships are not secured.
There is uncertainty regarding the regulatory approval path for BioAtla Inc (BCAB)'s product candidates, as they await further guidance from the FDA.
The company has not yet finalized the indication for their expansion cohort study, which could delay progress in clinical trials.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BCAB.OQ - Bioatla Inc
Q2 2025 Bioatla Inc Earnings Call
Aug 07, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day everyone, and welcome to the Bio Atlas 2nd quarter 2025 earnings call. At this time, all participants are in a listen-only mode. Later you'll have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing the star and 1 on your telephone keypad. We will be standing by if you should need any assistance, and it is my pleasure to turn today's conference over to Christy Grabowski with Life Science Advisors. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
With me today on the phone from BioAa are Dr. Jay

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.